京新藥業(002020.SZ):左乙拉西坦片通過一致性評價
格隆匯3月27日丨京新藥業(002020.SZ)公佈,公司於近日收到國家藥監局核准簽發的化學藥品“左乙拉西坦片”的《藥品補充申請批件》,該藥品通過仿製藥一致性評價。
左乙拉西坦是比利時UCB公司開發研製的一種新型抗癲癇藥物,2006年11月獲得SFDA批准進口中國,用於成人及4歲以上兒童癲癇患者部分性發作的加用治療。
公司左乙拉西坦片(0.25g)已於2018年5月國內首家通過仿製藥質量和療效一致性評價,此次0.5g、1.0g兩個規格通過一致性評價,可為患者提供更多的用藥選擇,提高患者長期用藥的依從性,也有利於提高該產品的市場競爭力,對公司的經營業績產生積極的影響,同時為公司後續其他產品開展仿製藥一致性評價工作積累經驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.